PDCD1 and glioblastoma: Our study cohort included 30 patients with resectable GBM recurrence, 20 of whom were enrolled in the CA209-9UP trial, an open-label phase II study evaluating nivolumab, a PD-1 inhibitor, for recurrent GBM [47].